EKF Diagnostics Holdings plc (FRA:LYF)

Market Cap	122.88M -13.1%
Revenue (ttm)	58.59M -1.4%
Net Income	7.14M +28.1%
EPS	0.02 +28.3%
Shares Out	n/a
PE Ratio	17.21
Forward PE	16.89
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.2820
Previous Close	0.2840
Day's Range	0.2680 - 0.2820
52-Week Range	0.2680 - 0.3080
Beta	n/a
RSI	40.29
Earnings Date	Mar 23, 2026

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Cl...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1990
• Employees: 297
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LYF

Financial Performance

In 2024, EKF Diagnostics Holdings's revenue was 50.19 million, a decrease of -4.59% compared to the previous year's 52.61 million. Earnings were 6.24 million, an increase of 165.39%.

Financial numbers in GBP